Syndax Pharmaceuticals, Inc.
SNDX
$10.99
$0.292.71%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 160.96% | -38.56% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 160.96% | -38.56% | |||
| Cost of Revenue | -98.67% | -6.50% | |||
| Gross Profit | 132.65% | -0.35% | |||
| SG&A Expenses | 8.86% | 21.17% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.47% | 1.93% | |||
| Operating Income | 13.34% | -7.58% | |||
| Income Before Tax | 9.90% | -11.94% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 9.90% | -11.94% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 9.90% | -11.94% | |||
| EBIT | 13.34% | -7.58% | |||
| EBITDA | 13.34% | -7.58% | |||
| EPS Basic | 10.30% | -11.48% | |||
| Normalized Basic EPS | 10.29% | -11.47% | |||
| EPS Diluted | 10.30% | -11.48% | |||
| Normalized Diluted EPS | 10.29% | -11.47% | |||
| Average Basic Shares Outstanding | 0.44% | 0.42% | |||
| Average Diluted Shares Outstanding | 0.44% | 0.42% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||